Biocon stock zooms 9% on Psoriasis drug approval from Japan, Jefferies rating upgrade
Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.
Why are Zomato, Biocon and ONGC shares buzzing today?
Analyst revisions kept stocks of Zomato, Biocon, and ONGC in focus on Monday. While Zomato’s share price was down by 4.8% ...
Stock Radar: Biocon stock price breaks out from upper band of a Symmetrical Triangle; should you buy?
Biocon Ltd has broken out of the Symmetrical Triangle formation on daily charts, suggesting a potential rise in stock price.
F&O Query: Should you hold Biocon put option?
Hold Biocon 320-put option as stock may drop to ₹350, with potential for premium increase. Contact [email protected] ...
Biocon share rises 4% as arm gets Japan's PMDA approval for Psoriasis drug
The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...
cnbctv182d
Biocon shares gain 8% after Psoriasis drug approval from Japan, Jefferies upgrade
Biocon Biologics had entered into a settlement and licensing agreement with Janssen Biotech Inc. and Janssen Sciences Ireland ...
Biocon shares zoom 8% after Jefferies upgrade to 'hold', price target lifted by 43%
Optimism for Biocon is fuelled by the green light for its Bengaluru biologics unit, paired with the USFDA approval for the launch of its Stelara biosimilar for autoimmune disorders, ...
Biocon Biologics marks one year as global biosimilars enterprise
Biocon’s subsidiary, Biocon Biologics Limited (BBL), has announced the completion of its first year as a fully integrated ...
Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 target
This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concerning ...
cnbctv187d
Biocon arm Biocon Pharma receives approval for Tacrolimus capsules in China
"This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the company, has received approval for ...
Biocon shares surge 7.79% on approval of Ustekinumab biosimilar in Japan
Biocon's biosimilar Ustekinumab receives regulatory approval in Japan, with Yoshindo Inc. handling commercialization and ...
Biocon is a good buy on dip stock; likely to hit fresh 52-week highs
Biocon stock price has broken out from the upper band of a Symmetrical Triangle formation, indicating a positive movement. Traders can buy for a target of Rs 403-436 in the next 3-4 weeks,” Kkunal V.